Skip to content
Catalyst

PapersPMID:40676704

Multi-omics analyses the effect of Bifidobacterium longum subsp. longum BL21 supplementation on overweight and obese subjects: a randomized, double-blind, placebo-controlled study.

Nutrition & metabolism2025The record ↗

  1. Finding, moderate evidenceno difference foundBody mass

No finding here moved its endpoint.

What did not

1 findingHow to read these marks →
  • “As shown in Table 2, both the BL21 group (P = 0.02) and placebo group (P = 0.01) demonstrated significant body weight reductions, with no statistically significant intergroup difference observed (P = 0.81).”
    Study
    RCT
    Duration
    8 weeks
    Interests
    Industry funded
    Dose studied
    once daily for 8 weeks, 2 × 1010 CFU/day with 3 g maltodextrin per day, oral powder
    Population
    Overweight and obese adults aged 18-65 (BMI above 24 kg/m2); per-protocol set of 33 per arm; placebo was maltodextrin

Study record

Design
randomised controlled trial
Species
human
Population
overweight and obese adults aged 18 to 65 years with BMI above 24 kg/m2
Participants
72
Comparator
placebo
Duration
56 days
Endpoints measured
31